News
ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Update
ESSA Pharma Inc. Reports Results of Annual General & Special Meeting of Shareholders
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 21, 2019
ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2019
ESSA Pharma Presents Data on EPI-7386 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
ESSA Announces Changes to its Board of Directors
ESSA Pharma Board of Directors Approves Stock Option Plan RSU Plan and Option Grants
ESSA Pharma Presents New Data on EPI-7386 at the European Society of Medical Oncology (ESMO) 2019 Congress
ESSA to Present at Ladenburg Thalmann Healthcare Conference